ទំព័រដើម › ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ › អូហាយ៉ូ › Columbus
ការសាកល្បងគ្លីនិកសម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ នៅក្នុង Columbus, OH
ការសិក្សាចំនួន 35 សម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Columbus (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Ivosidenib as Post-HSCT Maintenance for AML
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- និង 8 ទៀត
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Comprehensive Cancer Center, Columbus
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- Nationwide Children's Hospital, Columbus
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University, The James Comprehensive Cancer, Columbus
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio Sate University, Columbus
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
កំពុងជ្រើសរើសដំណាក់កាល 3
- US-Colombus OH-OSU, Columbus
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- OhioHealth Research Institute, Columbus
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
កំពុងជ្រើសរើសដំណាក់កាល 3
- US-Colombus OH-OSU, Columbus
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Nationwide Children's Hospital, Columbus
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Comprehensive Cancer Center, Columbus
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Nationwide Children's Hospital, Columbus
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
កំពុងជ្រើសរើសដំណាក់កាល 3
- Ohio State University, Columbus
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Nationwide Children's Hospital, Columbus
- The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Ohio State University Comprehensive Cancer Center, Columbus
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
កំពុងជ្រើសរើសដំណាក់កាល 1
- The Ohio State University, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Ziftomenib Maintenance Post Allo-HCT
កំពុងជ្រើសរើសដំណាក់កាល 1
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
កំពុងជ្រើសរើសដំណាក់កាល 1
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
កំពុងជ្រើសរើសដំណាក់កាល 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- The Ohio State University Medical Center, Columbus
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The Ohio State University Wexner Medical Center, Columbus
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Ohio State University, Columbus
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Nationwide Children's Hospital, Columbus
ការសាកល្បងសម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 85
- New York City, NYការសិក្សា 51
- Boston, MAការសិក្សា 44
- Seattle, WAការសិក្សា 41
- Baldwin Park, CAការសិក្សា 40
- Philadelphia, PAការសិក្សា 34
- Durham, NCការសិក្សា 33
- Atlanta, GAការសិក្សា 31
- Tampa, FLការសិក្សា 29
- Chicago, ILការសិក្សា 26
- Portland, ORការសិក្សា 25
- Washington, DCការសិក្សា 24
ការសិក្សាផ្សេងទៀតនៅក្នុង Columbus
- Non-Small Cell Lung Cancerការសិក្សា 57
- មហារីកទ្រូងការសិក្សា 40
- មហារីកស៊ុតការសិក្សា 39
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 38
- មហារីកសួតការសិក្សា 37
- ជំងឺលីម្វូស៊ីតប្រចាំការសិក្សា 28
- មហារីកដែលរីករាលដាលការសិក្សា 27
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 25
- មហារីកតូចការសិក្សា 24
- ជំងឺ Multiple Myelomaការសិក្សា 24
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 24
- មេឡាណូម៉ាការសិក្សា 21
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។